Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a Healthcare company (Biotechnology) with a market capitalization of $808M. The Maz Rating grades it against the other companies in its sector.
Rigel Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $42.92, Rigel Pharmaceuticals, Inc. trades at 2.5x trailing earnings, 2.8x sales and 1.8x book value, with an EV/EBITDA of 9.2. Over the last twelve months it generated about $291M of revenue and $320M of net income. It runs a gross margin of 89.6%, an operating margin of 26.3% and a net margin of 106.6%. It shows return on equity of 73.9%, return on invested capital of 16.7% and a free cash flow yield of 11.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 2.39. Over the past 52 weeks the share price ranged from $24.95 to $52.61, with a beta of 1.24.
Rigel Pharmaceuticals, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 8 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Rigel Pharmaceuticals, Inc. (RIGL) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.83% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.4% / 30% · Interest income / Revenue 0.69% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.83% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.4% / 33% · Receivables / Mkt Cap (36m) 6.46% / 49% · Interest income / Revenue 0.69% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.83% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.4% / 33.33% · Receivables / Mkt Cap (24m) 6.46% / 33.33% · Interest income / Revenue 0.69% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 6.99% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24.1% / 33.33% · Receivables / Avg Assets (4Q) 10.4% / 33.33% · Interest income / Revenue 0.69% / 5% | Pass |
| FTSE | Debt / Total Assets 1.38% / 33.33% · (Cash+ST Inv) / Total Assets 19.0% / 33.33% · (Cash+Recv) / Total Assets 29.7% / 33.33% · Interest income / Revenue 0.69% / 5% | Pass |
Yes. As of September 2026, Rigel Pharmaceuticals, Inc. (RIGL) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Rigel Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.69% of each dividend: Rigel Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.